IBTR! 2.0: 10-year Ipsilateral Breast Tumor Recurrence (without RT)
The Ipsilateral Breast Tumor Recurrence (IBTR) 2.0 is designed for use by physicians to guide medical decision-making regarding the use of radiation therapy in breast cancer patients who have undergone breast conserving surgery and appropriate axillary evaluation. This model calculates an evidence-based estimate of the 10-year ipsilateral breast tumor recurrence risk with and without the addition of whole breast radiation therapy. 

The IBTR 2.0 is not intended for use in the post-mastectomy setting, and it is not meant to address patients with multicentric disease or with in-situ only disease. It is assumed that all pathological specimens have been microscopically assessed with current histopathological standards. It is presumed that patients who are lymph node positive (with the exception of micrometastatic lymph node disease) will receive systemic therapy, either chemotherapy or hormonal therapy. The calculated benefit of hormonal therapy in this model is based on the tamoxifen literature and has been extrapolated to the use of aromatase inhibitors. Recent studies indicate that aromatase inhibitors have a similar, and possibly a slightly superior, impact on local control. 
Research authors: Mona Sanghani, Pauline T. Truong, Rita Abi Raad, Andrzej Niemierko, Mary Lesperance, Ivo A. Olivotto, David E. Wazer, Alphonse G. Taghian
Version: 1.3
  • Details
  • Validate model
  • Save input
  • Load input

Calculate the result

Set more parameters to perform the calculation

10-Year risk of ipsilateral breast tumor recurrence without radiation therapy is: %

{{ resultSubheader }}
{{ chart.title }}
Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

Conditional information

The arm of the IBTR! nomogram that calculates local recurrence risk with radiation has undergone rigorous validation testing with collaboration of two large institutional datasets. The calculation of local recurrence risk without radiation has not been validated because of unavailability of a large diverse cohort of patients that did not receive radiation therapy. Therefore the predicted recurrence risk without radiation therapy is based on the consistent relative risk reduction of 0.7 seen across multiple randomized trials with the use of breast irradiation.

{{ file.classification }}
PRO
Note
Notes are only visible in the result download and will not be saved by Evidencio

This model is provided for educational, training and information purposes. It must not be used to support medical decision making, or to provide medical or diagnostic services. Read our full disclaimer.

Underlying models Part of
Comments
Comment
Please enter a comment
Comments are visible to anyone

Model feedback

No feedback yet 1 Comment {{ model.comments.length }} Comments
On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
{{ comment.content }}
logo

Please sign in to enable Evidencio print features

In order to use the Evidencio print features, you need to be logged in.
If you don't have an Evidencio Community Account you can create your free personal account at:

https://www.evidencio.com/registration

Printed results - Examples {{ new Date().toLocaleString() }}


Evidencio Community Account Benefits


With an Evidencio Community account you can:

  • Create and publish your own prediction models.
  • Share your prediction models with your colleagues, research group, organization or the world.
  • Review and provide feedback on models that have been shared with you.
  • Validate your models and validate models from other users.
  • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction models and their data.
  • Use patient specific protocols and guidelines based on sequential models and decision trees.
  • Stay up-to-date with new models in your field as they are published.
  • Create your own lists of favorite models and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.


Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.
Evidencio v3.25 © 2015 - 2024 Evidencio. All Rights Reserved